Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Targeting APT2 improves MAVS palmitoylation and antiviral innate immunity.

Lang Bu | Huan Wang | Shuishen Zhang | Yi Zhang | Miaowen Liu | Zhengkun Zhang | Xueji Wu | Qiwei Jiang | Lei Wang | Wei Xie | Miao He | Zhengran Zhou | Chao Cheng | Jianping Guo
Molecular cell | 2024

Innate immunity serves as the primary defense against viral and microbial infections in humans. The precise influence of cellular metabolites, especially fatty acids, on antiviral innate immunity remains largely elusive. Here, through screening a metabolite library, palmitic acid (PA) has been identified as a key modulator of antiviral infections in human cells. Mechanistically, PA induces mitochondrial antiviral signaling protein (MAVS) palmitoylation, aggregation, and subsequent activation, thereby enhancing the innate immune response. The palmitoyl-transferase ZDHHC24 catalyzes MAVS palmitoylation, thereby boosting the TBK1-IRF3-interferon (IFN) pathway, particularly under conditions of PA stimulation or high-fat-diet-fed mouse models, leading to antiviral immune responses. Additionally, APT2 de-palmitoylates MAVS, thus inhibiting antiviral signaling, suggesting that its inhibitors, such as ML349, effectively reverse MAVS activation in response to antiviral infections. These findings underscore the critical role of PA in regulating antiviral innate immunity through MAVS palmitoylation and provide strategies for enhancing PA intake or targeting APT2 for combating viral infections.

Pubmed ID: 39255795

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


IRF-3 (D6I4C) XP® (antibody)

RRID:AB_2722521

This monoclonal targets IRF3

View all literature mentions

Protein A/G PLUS-Agarose (antibody)

RRID:AB_10201400

This unknown targets Protein A/G PLUS-Agarose

View all literature mentions

ZDHHC24 Polyclonal Antibody (antibody)

RRID:AB_2884584

This polyclonal targets ZDHHC24

View all literature mentions

MAVS (D5A9E) Rabbit mAb (antibody)

RRID:AB_2798889

This monoclonal targets MAVS

View all literature mentions

ANTI-FLAG(R) M2 Affinity Gel (antibody)

RRID:AB_10063035

This unknown targets ANTI-FLAG(R) M2 Affinity Gel

View all literature mentions

GST (91G1) Rabbit mAb (antibody)

RRID:AB_490796

This monoclonal targets GST (91G1) Rabbit mAb

View all literature mentions

Phospho-IRF-3 (Ser396) (D6O1M) (antibody)

RRID:AB_2773013

This monoclonal targets Phospho-IRF-3 (Ser396)

View all literature mentions

Myc-Tag (9B11) Mouse mAb (antibody)

RRID:AB_331783

This monoclonal targets c-Myc

View all literature mentions

GAPDH (D16H11) XP Rabbit mAb (antibody)

RRID:AB_10622025

This monoclonal targets GAPDH

View all literature mentions

TBK1/NAK (E8I3G) (antibody)

RRID:AB_2827657

This monoclonal targets TBK1

View all literature mentions

LYPLA2 Polyclonal Antibody (antibody)

RRID:AB_2609917

This polyclonal targets LYPLA2

View all literature mentions